Mirum Pharmaceuticals Inc (MIRM)
25.72
+0.61
(+2.43%)
USD |
NASDAQ |
May 01, 16:00
25.72
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Cash from Operations (TTM): -70.94M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -70.94M |
September 30, 2023 | -88.60M |
June 30, 2023 | -96.40M |
March 31, 2023 | -114.24M |
December 31, 2022 | -120.14M |
September 30, 2022 | -119.01M |
June 30, 2022 | -127.19M |
March 31, 2022 | -147.22M |
December 31, 2021 | -132.76M |
Date | Value |
---|---|
September 30, 2021 | -135.89M |
June 30, 2021 | -119.14M |
March 31, 2021 | -95.93M |
December 31, 2020 | -89.08M |
September 30, 2020 | -66.49M |
June 30, 2020 | -64.26M |
March 31, 2020 | -55.29M |
December 31, 2019 | -39.36M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-147.22M
Minimum
Mar 2022
-39.36M
Maximum
Dec 2019
-98.94M
Average
-96.40M
Median
Jun 2023
Cash from Operations (TTM) Benchmarks
Gilead Sciences Inc | 8.481B |
Vanda Pharmaceuticals Inc | 12.80M |
Sarepta Therapeutics Inc | -500.99M |
Puma Biotechnology Inc | 27.01M |
Reneo Pharmaceuticals Inc | -63.68M |